Press Room

Find news and updates from PhRMA, representing the country’s leading biopharmaceutical research companies. Our members are committed to finding tomorrow’s cures and treatments for some of the most serious diseases such as cancer, Alzheimer’s disease, cystic fibrosis and Parkinson’s.

Latest News from PhRMA

SB 17 doesn’t address pressing prescription drug transparency issues for CA voters

August 30, 2017

Does the promise of SB 17 align with the needs of Californians?

Read More

PhRMA Announces Dr. Richard Moscicki as New Chief Medical Officer and Executive Vice President

August 30, 2017

PhRMA today announced Richard A. Moscicki, M.D. will join the organization as chief medical officer and executive vice president.

Read More

Medicare Monday: Call for repeal of IPAB intensifies

August 28, 2017

A look at the growing bipartisan opposition to IPAB.

Read More

Medicare Monday: What is the Extra Help program?

August 21, 2017

Medicare Part D’s Extra Help program helps low-income beneficiaries better afford their medicines.

Read More

PhRMA Statement on President Trump’s Signing of PDUFA VI Reauthorization

August 18, 2017

PhRMA president and CEO Stephen J. Ubl issued the following statement.

Read More

Medicare Monday: Strengthening access to vaccines for seniors

August 14, 2017

Importance of access to vaccines for seniors

Read More

Medicare Monday: Part D premiums expected to drop in 2018

August 7, 2017

CMS announced Medicare Part D prescription drug plan premiums are projected to drop.

Read More

ICYMI: New report outlines steps for greater transparency in health care

August 4, 2017

A new report outlines steps for greater transparency in health care.

Read More

PhRMA Statement on Senate Passage of PDUFA VI Reauthorization

August 3, 2017

PhRMA applauds the Senate for passage of the Prescription Drug, Biosimilar and Generic Drug User Fee Acts.

Read More

PhRMA Supports President’s Commission’s Holistic Approach on Opioid Crisis

August 2, 2017

President’s Commission on Combatting Drug Addiction and the Opioid Crisis report reflects an approach that America’s biopharmaceutical companies support.

Read More